New therapeutic approach in the management of intestinal disease: probiotics in intestinal disease in paediatric age.
Current evidence supports the view that oral administration of probiotics may be of therapeutic usefulness in several clinical disorders by reestablishing normal flora in the gastrointestinal tract. These entities include inflammatory and infectious diseases of the gut as well as extraintestinal disorders (such as atopic eczema) in which a defective intestinal permeability plays a role. The probiotic effects are attributed to restoration to normal of increased intestinal permeability, unbalanced gut microecology, improved immunological gut barrier function, downregulation of the intestinal inflammatory responses with reduced generation of proinflammatory cytokines. Entities for which the impact of probiotic administration can be considered as proven are Rotavirus diarrhoea, Clostridium difficile diarrhoea, post-antibiotic diarrhoea, allergic diseases. On the other hand, entities for which administration of probiotics is considered under investigation are inflammatory bowel disease, necrotizing enterocolitis, cystic fibrosis, small bowel bacterial contamination, functional gastrointestinal disorders. The value of probiotics as therapy for a variety of gastrointestinal disorders in childhood still needs to be investigated in detail, through well controlled and rigorous studies, including a placebo group and strict criteria of randomisation. Much work needs to be done in this area by clearly defining indications, delivery system, costs, safety long-term effects.
Cucchiara
S
S
Pediatric Gastroenterology and Gastrointestinal Endoscopy Unit, Department of Paediatrics, Rome, Italy. salvatore.cucchiara@uniroma1.it
Falconieri
P
P
Di Nardo
G
G
Parcelii
M A
MA
Dito
L
L
Grandinetti
A
A
D002648:Child; D005767:Gastrointestinal Diseases / Q000628:therapy; D006801:Humans; D007408:Intestinal Absorption; D007410:Intestinal Diseases / Q000628:therapy*; D007422:Intestines / Q000382:microbiology*; D019936:Probiotics / Q000627:therapeutic use*